Cardiovascular and kidney outcomes of <scp>GLP</scp> ‐1 receptor agonists in adults with obesity: A target trial emulation study
Among adults with obesity but without diabetes, GLP-1RA use was associated with reduced cardiovascular, kidney, mortality, and mental health risks compared to other AOMs.
Authors
- Yiwen Lu (ORCID: https://orcid.org/0009-0000-9591-2261)
- Dazheng Zhang (ORCID: https://orcid.org/0000-0002-1431-0785)
- David A. Asch (ORCID: https://orcid.org/0000-0002-7970-286X)
- Huilin Tang (ORCID: https://orcid.org/0000-0002-5814-6657)
- Jiajie Chen (ORCID: https://orcid.org/0009-0008-7402-6883)
- Bingyu Zhang
- Ting Zhou (ORCID: https://orcid.org/0000-0003-3392-2979)
Institutions
- Pfizer (United States) (US)
- Penn Center for AIDS Research (US)
- Applied Mathematics (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1111/dom.70054
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- National Institutes of Health
- NIH Clinical Center